Biosimilars, Drug Development and White Paper

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Biosimilars

Drug Development

White Paper

The Brazilian pharma market: Key information and what may change

Pharmaceutical Technology

DECEMBER 9, 2022

Instead, the focus remains on its domestic industry, particularly around biosimilars, while reducing reliance on imports and branded pharmaceuticals. <p>Early Access Programs (EAPs) are a pathway for pharmaceutical companies to provide innovative drugs to patients living with serious conditions.

Drug Pricing

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Biosimilars

Quality by design with a focus on biosimilars

Pharmaceutical Technology

OCTOBER 28, 2022

Practising QbD in biosimilar product development. One area in which QbD should be practised is that of biosimilars, also known as follow-on biologics or subsequent entry biologics. Biosimilars are biologic medical products that almost exactly replicate products already being manufactured by other companies.

Pharmacist Digest

The Brazilian pharma market: Key information and what may change

Quality by design with a focus on biosimilars

Stay Connected